PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
Main Authors: | Rania Gaspo, Rowan Claeys, Jerome Sallette |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975356.67572.1c |
Similar Items
-
PB2000: LESSONS LEARNED FROM CERBA RESEARCH CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) MULTIPLE MYELOMA RUNNING TRIALS
by: R. Gaspo, et al.
Published: (2022-06-01) -
2149
by: Maureen Byrne, et al.
Published: (2017-09-01) -
Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
by: Angelo Maiolino, et al.
Published: (2023-05-01) -
Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)
by: Roger G. Owen
Published: (2019-06-01) -
P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Tereza Popková, et al.
Published: (2023-08-01)